There are multiple chapters near you. Select your preferred chapter.

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

Dysregulation of the alternative complement pathway, hallmarked by isolated reduction of the serum C3 fraction, is now recognized as an additional feature of lupus nephritis.

GSK (GSK) plc announced that the U.S. Food and Drug Administration has approved a 200 mg/mL autoinjector of Benlysta, a B-lymphocyte ...

New research by Swansea University and the University of Cambridge has revealed the causes and devastating impacts of delays – that can last decades - in diagnosing lupus, an auto-immune condition.